In conclusion, in the context of a tertiary referral NHS Cancer Centre neoadjuvant chemotherapy in combination with trastuzumab and pertuzumab is a safe and efficacious treatment for early HER2 breast cancer. Here, ERBB2 is linked to breast cancer.